An interventional study of Dexamethasone and Dexmedetomidine in Supraclavicular Brachial Plexus Block, sponsored by Muhammad Aamir Latif. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Muhammad Aamir Latif · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Various adjuvants, including dexamethasone and dexmedetomidine, have been explored to improve block quality and prolong postoperative analgesia. However, local evidence comparing their efficacy is limited. Therefore, this study aims to compare bupivacaine plus dexamethasone versus bupivacaine plus dexmedetomidine in terms of onset and duration of sensory and motor blockade and postoperative analgesia.
Although local anesthetics like bupivacaine, known for their long duration of action, are frequently employed for Supraclavicular Brachial Plexus Block (SCBP), the limited duration of postoperative analgesia remains a challenge. To address this, various adjuvants, such as opioids, midazolam, magnesium sulfate, neostigmine, dexamethasone, and dexmedetomidine, have been explored to enhance block quality, prolong analgesia, and reduce side effects. Dexmedetomidine, a selective α2-adrenoceptor agonist, has demonstrated efficacy in extending sensory and motor blockade when combined with local anesthetics. Similarly, dexamethasone, a potent glucocorticoid with anti-inflammatory and analgesic properties, has shown promising results in prolonging block duration by inhibiting nociceptive fiber transmission and neuronal discharge. However, the comparative benefits of these adjuvants warrant further evaluation, as identifying the more effective option may help optimize block characteristics, improve postoperative pain control, reduce analgesic requirements, and enhance patient satisfaction.
Muhammad Aamir Latif is the lead sponsor of 59 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients were administered 20 mL of 0.5% bupivacaine with 4 mg (1 mL) of dexamethasone.
Drug: Dexamethasone
Patients were given 20 mL of 0.5% bupivacaine with 1 µg/kg (2 mL) of dexmedetomidine.
Drug: Dexmedetomidine
Patients were administered 20 mL of 0.5% bupivacaine with 4 mg (1 mL) of dexamethasone.
Patients were given 20 ml of 0.5% bupivacaine with 1 µg/kg (2 ml) of dexmedetomidine.
Onset and duration of sensory blockade
Onset of sensory blockade is defined as the time elapsed from anesthetic injection to complete loss of pinprick sensation (score 2). Duration is defined as the interval between achieving complete sensory blockade (score 2) and full return of sensation (score 0) in the blocked dermatomes. Both are measured in minutes.
Time frame: Perioperative period, i.e., up to 24 hours after anesthetic administration.
Onset and duration of motor blockade
Onset of motor blockade is defined as the time elapsed from anesthetic injection to complete loss of muscle power (score 2). Duration is defined as the interval between achieving complete motor blockade (score 2) and full recovery of hand and forearm muscle function (score 0), measured in minutes.
Time frame: Perioperative period, i.e., up to 24 hours after anesthetic administration.
Duration of postoperative analgesia
Defined as the time elapsed from anesthetic administration to the first request for rescue analgesia, indicated by a Visual Analogue Scale (VAS) score of 4, measured in minutes.
Time frame: Postoperative period, i.e., up to 24 hours after anesthetic administration.
Plan to share: No — Data can be shared on a reasonable request.
No publications or documents are linked to this record.
Ran from Oct 2025 to primary completion in Mar 2026, 5 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexamethasone · Dexmedetomidine
Muhammad Aamir Latif